From Wikipedia, the free encyclopedia
(Redirected from Axert)
Jump to navigation Jump to search
Almotriptan skeletal.svg
Ball-and-stick model of the almotriptan molecule
Clinical data
Trade namesAxert
License data
Routes of
By mouth
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
  • US: ℞-only [1][2]
  • EU: Rx-only [3]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding35%
Elimination half-life3–4 hours
  • N,N-dimethyl-2- [5-(pyrrolidin-1-ylsulfonylmethyl)- 1H-indol-3-yl]-ethanamine
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass335.47 g·mol−1
3D model (JSmol)
  • CN(C)CCc2c[nH]c3ccc(CS(=O)(=O)N1CCCC1)cc23
  • InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3 checkY
 ☒NcheckY (what is this?)  (verify)

Almotriptan (trade name Axert and others) is a triptan medication discovered and developed by Almirall for the treatment of heavy migraine headache.

It was patented in 1992 and approved for medical use in 2000.[4]

Medical uses[edit]

Almotriptan is prescribed to treat the acute headache phase of migraine attacks with or without aura.[5] Almotriptan is the only oral triptan approved in the US for the treatment of migraine in adolescent from 12 to 17 years of age.[citation needed]


The efficacy and tolerability of almotriptan has been studied in numerous randomised, controlled trials totaling more than 4800 adults with either moderate or severe attacks of migraine. Its efficacy is significantly more effective than placebo and alleviates nausea, photophobia and phonophobia linked to migraine attacks. Almotriptan has similar efficacy as a standard dose of sumatriptan, another triptan drug, and fewer adverse effects.[6]


As with other triptans, almotriptan should not be used in patients with a history, symptoms or signs of ischaemic heart disease (myocardial infarction, angina pectoris, documented silent ischaemia, Prinzmetal's angina) or severe hypertension and uncontrolled mild or moderate hypertension. Other contraindications are previous cerebrovascular accident (CVA) or transient ischaemic attack (TIA), peripheral vascular disease, severe hepatic impairment, concomitant administration of ergotamine, ergotamine derivatives (including methysergide) and other 5-HT1B/D agonists.

Side effects[edit]

Almotriptan has proved to have an adverse effects profile similar to placebo when used following the Summary of Product Characteristics instructions (see references).


Mechanism of action[edit]

Like all triptans, almotriptan has a high and specific affinity for serotonin 5-HT1B/1D receptors. Binding of the drug to the receptor leads to vasoconstriction of the cranial (brain) blood vessels and thus affects the redistribution of blood flow. Almotriptan significantly increases cerebral blood flow and reduces blood flow through extracerebral cranial vessels. Even though it affects cranial blood vessels a single standard dose of almotriptan has no clinically significant effect on blood pressure or heart rate in both young and elderly healthy volunteers. Larger doses seem to slightly increase blood pressure but not beyond clinical relevance.[6]


Almotriptan has linear pharmacokinetics up to the 16-fold standard dose. Its biological half-life is 3 hours, and its bioavailability 70%. Cmax is observed 1.5–4 hours after oral administration, and approximately 50% of the drug is excreted unchanged in the urine. Metabolism is mediated through the enzymes MAO-A and CYP3A4 and CYP2D6 oxidation. Almotriptan clearance is moderately reduced in the elderly but does not require dose adjustment. Sex does not alter the pharmacokinetics of the drug. People with moderate-to-severe renal dysfunction are recommended to use only half the dose.[7]


Almotriptan is metabolized mainly by MAO-A and to lesser extent by CYP3A4 and CYP2D6. Studies of drugs used as preventive against migraine (propranolol and verapamil), anti-depressants (moclobemide and fluoxetine) yielded results that showed significant altering of the pharmacokinetics of almotriptan though they were deemed not clinically relevant.[6]

Society and culture[edit]

Brand names[edit]

Brand names include Axert (US, Canada), Almogran (Belgium, Denmark, Finland, France, Germany, Italy, Ireland Portugal, Spain, the United Kingdom, the Netherlands, Sweden, Switzerland, South Korea...), Almotrex (Italy), Almozen (Bulgaria and Poland) and Amignul (Spain).


  1. ^ "Almotriptan tablet, film coated". DailyMed. Retrieved 17 February 2021.
  2. ^ "Axert- almotriptan malate tablet, coated". DailyMed. Retrieved 17 February 2021.
  3. ^ "Active substance: almotriptan" (PDF). List of nationally authorised medicinal products. Europeans Medicines Agency. 11 February 2021.
  4. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 531. ISBN 9783527607495.
  5. ^ "Almotriptan Facts and Comparisons". Retrieved 7 October 2012.
  6. ^ a b c Keam SJ, Goa KL, Figgitt DP (2002). "Almotriptan: a review of its use in migraine". Drugs. 62 (2): 387–414. doi:10.2165/00003495-200262020-00010. PMID 11817980. S2CID 242752549.
  7. ^ McEnroe JD, Fleishaker JC (2005). "Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine". Clinical Pharmacokinetics. 44 (3): 237–246. doi:10.2165/00003088-200544030-00002. PMID 15762767. S2CID 23136754.

External links[edit]